Published in J Pathol on February 01, 2002
Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet (2013) 4.61
Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res (2008) 4.02
Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas. Am J Surg Pathol (2011) 1.76
Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer. Eur Urol (2015) 1.56
Alterations in VHL as potential biomarkers in renal-cell carcinoma. Nat Rev Clin Oncol (2010) 1.55
Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma. Clin Cancer Res (2009) 1.49
Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer (2008) 1.43
Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors. PLoS Genet (2011) 1.43
Prognostic factors in renal cell carcinoma. World J Urol (2010) 1.34
VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy. Curr Oncol Rep (2009) 1.25
Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers. Eur Urol (2014) 1.21
Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma. Br J Cancer (2009) 1.03
Prognostic significance of Gremlin1 (GREM1) promoter CpG island hypermethylation in clear cell renal cell carcinoma. Am J Pathol (2009) 1.00
The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma. Clin Exp Metastasis (2014) 0.95
Targeted therapy for renal cell carcinoma: a new treatment paradigm. Proc (Bayl Univ Med Cent) (2007) 0.92
A procedure for tissue freezing and processing applicable to both intra-operative frozen section diagnosis and tissue banking in surgical pathology. Virchows Arch (2008) 0.89
Concomitant deregulation of HIF1alpha and cell cycle proteins in VHL-mutated renal cell carcinomas. Virchows Arch (2005) 0.88
Determination of angptl4 mRNA as a diagnostic marker of primary and metastatic clear cell renal-cell carcinoma. PLoS One (2010) 0.88
Identification and functional characterization of pVHL-dependent cell surface proteins in renal cell carcinoma. Neoplasia (2012) 0.86
Vascularity of primary and metastatic renal cell carcinoma specimens. J Transl Med (2013) 0.86
Integrative genome-wide expression profiling identifies three distinct molecular subgroups of renal cell carcinoma with different patient outcome. BMC Cancer (2012) 0.85
Relevance of nuclear and cytoplasmic von hippel lindau protein expression for renal carcinoma progression. Am J Pathol (2003) 0.84
PI3Kβ inhibitor TGX221 selectively inhibits renal cell carcinoma cells with both VHL and SETD2 mutations and links multiple pathways. Sci Rep (2015) 0.83
NF-κB inhibition by bortezomib permits IFN-γ-activated RIP1 kinase-dependent necrosis in renal cell carcinoma. Mol Cancer Ther (2013) 0.82
Prognostic role of microvessel density in patients with renal cell carcinoma: a meta-analysis. Int J Clin Exp Pathol (2014) 0.82
Tumor characterization and stratification by integrated molecular profiles reveals essential pan-cancer features. BMC Genomics (2015) 0.80
[Von-Hippel-Lindau gene mutation types. Association of gene expression signatures in clear cell renal cell carcinoma]. Pathologe (2008) 0.80
Mutational status of VHL gene and its clinical importance in renal clear cell carcinoma. Virchows Arch (2014) 0.78
A novel role of sphingosine kinase-1 in the invasion and angiogenesis of VHL mutant clear cell renal cell carcinoma. FASEB J (2015) 0.78
Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: hotspots, affected binding domains, functional impact on pVHL and therapeutic relevance. BMC Cancer (2016) 0.77
Decreased expression of receptor tyrosine kinase of EphB1 protein in renal cell carcinomas. Int J Clin Exp Pathol (2014) 0.76
Pazopanib for the treatment of patients with advanced renal cell carcinoma. Clin Med Insights Oncol (2010) 0.76
SENP1 promotes proliferation of clear cell renal cell carcinoma through activation of glycolysis. Oncotarget (2016) 0.75
Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: a meta-analysis and review. Oncotarget (2017) 0.75
A novel pVHL-independent but NEMO-driven pathway in renal cancer promotes HIF stabilization. Oncogene (2015) 0.75
Genetic and Chromosomal Aberrations and Their Clinical Significance in Renal Neoplasms. Biomed Res Int (2015) 0.75
[Molecular basis of targeted therapy in metastatic renal cancer]. Pathologe (2008) 0.75
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron (2004) 14.35
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med (2011) 12.52
Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet (2009) 10.34
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet (2011) 9.10
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76
Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet (2012) 6.61
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med (2010) 6.39
Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res (2002) 5.99
Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J Neurosci (2007) 5.68
Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature (2003) 5.57
Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med (2002) 5.34
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28
EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia (2008) 5.22
Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol (2002) 5.20
Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet (2007) 5.19
Frequent EpCam protein expression in human carcinomas. Hum Pathol (2004) 4.94
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov (2011) 4.80
Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant (2003) 4.54
Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database. PLoS Genet (2012) 4.27
Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology (2009) 4.03
The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol (2013) 3.68
Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation (2005) 3.57
SNCA variants are associated with increased risk for multiple system atrophy. Ann Neurol (2009) 3.55
HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol (2009) 3.37
Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet (2002) 3.32
Virtual autopsy as an alternative to traditional medical autopsy in the intensive care unit: a prospective cohort study. Ann Intern Med (2012) 3.29
Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res (2009) 3.17
Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell (2013) 3.08
Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. Lancet Oncol (2011) 3.01
Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res (2005) 2.85
Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J Clin Oncol (2011) 2.78
Downsides of robot-assisted laparoscopic radical prostatectomy: limitations and complications. Eur Urol (2009) 2.76
FAN1 mutations cause karyomegalic interstitial nephritis, linking chronic kidney failure to defective DNA damage repair. Nat Genet (2012) 2.74
Cognitive training in Parkinson disease: cognition-specific vs nonspecific computer training. Neurology (2014) 2.74
Prevalence of a tertiary Gleason grade and its impact on adverse histopathologic parameters in a contemporary radical prostatectomy series. Eur Urol (2008) 2.72
Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene (2003) 2.71
The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol (2013) 2.65
Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol (2009) 2.60
Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res (2004) 2.55
Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol (2010) 2.48
POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. Cancer Res (2003) 2.45
Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Nat Genet (2004) 2.44
The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study. Lancet Neurol (2008) 2.42
Marked gene transcript level alterations occur early during radical prostatectomy. Eur Urol (2007) 2.41
PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain (2005) 2.40
Prevalence of KIT expression in human tumors. J Clin Oncol (2004) 2.40
Multiple regions of alpha-synuclein are associated with Parkinson's disease. Ann Neurol (2005) 2.40
A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol (2013) 2.32
Expression and prognostic relevance of annexin A3 in prostate cancer. Eur Urol (2008) 2.32
Prevalent overexpression of prolyl isomerase Pin1 in human cancers. Am J Pathol (2004) 2.32
Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res (2005) 2.31
Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum Mol Genet (2005) 2.28
Osmotic nephrosis: acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solutes. Am J Kidney Dis (2008) 2.24
Olfactory dysfunction: common in later life and early warning of neurodegenerative disease. Dtsch Arztebl Int (2013) 2.22
Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. Cell Stem Cell (2013) 2.22
Single-cell expression profiling of dopaminergic neurons combined with association analysis identifies pyridoxal kinase as Parkinson's disease gene. Ann Neurol (2009) 2.21
Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol (2007) 2.20
Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology (2012) 2.18
Ultrasound-guided injection of the iliopsoas muscle with botulinum toxin in camptocormia. Mov Disord (2008) 2.15
High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat (2004) 2.14
The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Res Treat (2005) 2.10
Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry (2009) 2.09
Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. Cancer Res (2011) 2.08
Reliable detection of subclonal single-nucleotide variants in tumour cell populations. Nat Commun (2012) 2.06
Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer. Clin Cancer Res (2008) 2.06
The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol (2013) 2.05
Cloning of BCAS3 (17q23) and BCAS4 (20q13) genes that undergo amplification, overexpression, and fusion in breast cancer. Genes Chromosomes Cancer (2002) 2.04
Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann Neurol (2008) 2.04
Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol (2004) 2.04
Establishment of a multicolour fluorescence in situ hybridisation-based assay for subtyping of renal cell tumours. Eur Urol (2013) 2.00
pVHL and GSK3beta are components of a primary cilium-maintenance signalling network. Nat Cell Biol (2007) 1.97
Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. Int J Oncol (2004) 1.95
Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain. FASEB J (2007) 1.94
Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*. Brain (2005) 1.85
Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. Lancet Neurol (2013) 1.82
DACH1 is a cell fate determination factor that inhibits cyclin D1 and breast tumor growth. Mol Cell Biol (2006) 1.80
Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol (2012) 1.80
Parkinson patient fibroblasts show increased alpha-synuclein expression. Exp Neurol (2008) 1.79
DJ-1 and prevention of oxidative stress in Parkinson's disease and other age-related disorders. Free Radic Biol Med (2009) 1.78
Control of bone formation by the serpentine receptor Frizzled-9. J Cell Biol (2011) 1.77
ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res (2011) 1.75
Influence of slide aging on results of translational research studies using immunohistochemistry. Mod Pathol (2004) 1.75
Red flags for multiple system atrophy. Mov Disord (2008) 1.75
High incidence of EMMPRIN expression in human tumors. Int J Cancer (2006) 1.74
pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation. EMBO J (2008) 1.72
Absence of an orphan mitochondrial protein, c19orf12, causes a distinct clinical subtype of neurodegeneration with brain iron accumulation. Am J Hum Genet (2011) 1.70
Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol (2006) 1.69
PARK6-linked parkinsonism occurs in several European families. Ann Neurol (2002) 1.68
Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease. Hum Mol Genet (2012) 1.68
Arterial neovascularization and inflammation in vulnerable patients: early and late signs of symptomatic atherosclerosis. Circulation (2004) 1.68
Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study. Ann Surg Oncol (2009) 1.67
SOX4 expression in bladder carcinoma: clinical aspects and in vitro functional characterization. Cancer Res (2006) 1.66
SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer. Mod Pathol (2011) 1.66
Priorities in Parkinson's disease research. Nat Rev Drug Discov (2011) 1.66
Autoantibodies against beta-amyloid are common in Alzheimer's disease and help control plaque burden. Ann Neurol (2009) 1.65